I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Due to the potentially aggressive progression of coronary atherosclerosis, patients with premature coronary heart disease may have a higher risk of recurrent coronary events and repeat revascularization, especially patients with premature triple-vessel disease (PTVD).\[[@ref1][@ref2]\] Previous studies of premature coronary heart disease including small sample-size case reports of PTVD patients did not compare the three primary treatment strategies (percutaneous coronary intervention \[PCI\], coronary artery bypass grafting \[CABG\], and medical therapy \[MT\]) for prognosis.\[[@ref3]\] Therefore, the optimal treatment for PTVD patients remains controversial. Our study is to assess the long-term clinical outcomes following CABG, PCI, or MT alone in a large-scale clinical study of PTVD patients.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The study complied with the guidelines of the *Declaration of Helsinki*. The Ethics Committee of Fuwai Hospital approved the research protocol (Ethics application number: IRB2012-BG-006 and approval number: 2013-449), and all patients signed informed consent.

Patient selection {#sec2-2}
-----------------

All data were collected from the "Long-term Outcome of Triple-vessel Coronary Artery Disease Undergoing Three Different Strategies (LOTUS)" study (ClinicalTrials.gov ID: NCT02634086), a prospective cohort study that enrolled consecutive triple-vessel disease (TVD) patients in Fuwai Hospital (Beijing, China) from April 2004 to February 2011. PTVD patients were defined as men ≤50 years and women ≤60 years.\[[@ref4]\] TVD was defined as angiographic stenosis of ≥50% in all three main coronary arteries, left anterior descending (LAD), left circumflex, and right coronary artery. There were no predetermined exclusion criteria. For all patients accepting clinical follow-up and providing written informed consent, we recorded baseline demographics, procedural or operative characteristics, and outcome data in a dedicated independent research database. The Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score was calculated using the calculator: <http://www.syntaxscore.com> by a dedicated group of researchers blinded to the clinical data.\[[@ref5]\]

Procedures {#sec2-3}
----------

The selection of CABG or PCI was based on clinical and anatomical factors, contemporary treatment guidelines,\[[@ref6][@ref7]\] and patients' preferences. For the PCI group, all patients were prescribed acetylsalicylic acid (ASA) plus clopidogrel (loading dose: 300 mg) before the procedure. The techniques, devices, and drugs used during PCI were at the surgeon\'s discretion. Following stent implantation, patients received standard dual antiplatelet therapy, consisting of 100 mg/d ASA and 75 mg/d clopidogrel, for at least 12 months. For the CABG group, the internal mammary artery was chosen as the first graft to the LAD with standard bypass techniques. The choice of on-pump or off-pump procedure and whether to perform complete revascularization using arterial grafts was at the surgeon\'s discretion.

Patients not undergoing PCI or CABG either because of the risk associated with each revascularization procedure or the patient\'s or physician\'s preference underwent MT alone. All patients were prescribed an optimal medical regimen at baseline, which continued until the end of follow-up. This MT was tailored to each patient and included but was not limited to nitrates, ASA, clopidogrel, statins, beta-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, or a combination unless contraindicated and as recommended based on current practice, as for the other two groups.\[[@ref8][@ref9]\]

Follow-up and definition of the end points {#sec2-4}
------------------------------------------

The primary end point was all-cause death. The secondary end points were cardiac death, major adverse cardiovascular and cerebrovascular events, and a composite consisting of all-cause death, myocardial infarction, stroke, or repeat revascularization, or any one of these components. Causes of death were considered cardiac related unless an unequivocal noncardiac cause could be established. All outcome data were systematically collected since the index angiography. Information on in-hospital outcomes was obtained by medical record review, and long-term clinical outcome data were evaluated by telephone, follow-up letter, or patient visit on 6 and 12 months after the procedure, then annually thereafter. All adverse events were evaluated by a group of independent clinical physicians and carefully checked and confirmed. Investigators were trained, questionnaires blinded, and telephone interviews recorded for quality control, as shown in flow chat \[[Figure 1](#F1){ref-type="fig"}\].

![Flow chart of this study. TVD: Triple-vessel disease; CABG: Coronary artery bypass grafting; PCI: Percutaneous coronary intervention; MT: Medical therapy.](CMJ-131-1-g001){#F1}

Statistical analysis {#sec2-5}
--------------------

Continuous variables are presented as a mean ± standard deviation (SD), and categorical variables are presented as number with frequency. Normally distributed continuous variables were compared using the one-way analysis of variance test, and categorical variables were compared using Pearson\'s Chi-square test between groups. Survival curves were calculated using Kaplan-Meier estimates and compared with the log-rank test for end points. Cox proportional-hazards regression results are expressed as hazard ratios (*HR*s) with corresponding 95% confidence intervals (*CI*s) and compare long-term outcomes between groups. All clinically and statistically significant covariates were entered into the model with adjustments in the multivariate analysis for age, gender, hypertension, prior myocardial infarction, diabetes mellitus, hyperlipidemia, prior revascularization procedure, stroke, current smoking, family history of cardiovascular disease, and left ventricular ejection fraction (LVEF). The following factors were used in the multivariate cox regression analysis for subgroup analyses of assigned treatments: SYNTAX score (low risk: 0--22, intermediate risk: 22--32, or high risk: \>32), LVEF (\<40% or ≥40%), left main artery disease, gender, diabetes mellitus, prior myocardial infarction, and current smoking.

All statistical analyses were two sided with *P* \< 0.05 considered statistically significant. All statistical analyses were performed using SAS^®^ software (SAS Institute Inc., Chicago, IL, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Baseline characteristics {#sec2-6}
------------------------

A total of 1792 PTVD patients (20.0%) were registered among 8943 patients in the LOTUS registry. There were 933 (52.1%) patients treated with PCI, 459 (25.6%) with CABG, and 400 (22.3%) with MT alone. Patients undergoing PCI were younger, more likely to be male, had a higher incidence of acute myocardial infarction, lower incidence of previous myocardial infarction and diabetes mellitus, lower SYNTAX score, and lower proportion of LVEF \<40% compared with patients receiving CABG or MT alone \[[Table 1](#T1){ref-type="table"}\]. Compared with the PCI and CABG groups, the MT alone group had higher N-terminal-pro-brain natriuretic peptide levels, higher rates of LVEF \<40%, prior myocardial infarction, prior revascularization, and more comorbidities such as diabetes mellitus \[[Table 1](#T1){ref-type="table"}\].

###### 

Baseline characteristics of premature TVD patients

  Items                                      PCI group (*n* = 933)   CABG group (*n* = 459)   MT group (*n* = 400)   *P*
  ------------------------------------------ ----------------------- ------------------------ ---------------------- --------
  Epidemiology                                                                                                       
   Age (years), mean ± SD                    46.8 ± 6.0              49.2 ± 6.0               48.0 ± 6.6             \<0.01
   Female, *n* (%)                           206 (22.1)              162 (35.3)               118 (29.5)             \<0.01
   BMI (kg/m^2^), mean ± SD                  26.6 ± 3.1              26.4 ± 3.1               26.4 ± 3.4             0.42
   LVEF (%), mean ± SD                       60.8 ± 11.9             59.7 ± 12.7              56.0 ± 16.2            \<0.01
   LVEF \<40%, *n* (%)                       49 (5.3)                33 (7.3)                 74 (18.8)              \<0.01
  Risk factor and coronary condition                                                                                 
   Acute myocardial infarction, *n* (%)      320 (34.3)              53 (11.5)                104 (26.0)             \<0.01
   Previous myocardial infarction, *n* (%)   275 (29.5)              154 (33.6)               177 (44.3)             \<0.01
   Previous revascularization, *n* (%)       217 (23.3)              79 (17.2)                124 (31.0)             \<0.01
   Previous PCI, *n* (%)                     117 (12.5)              50 (10.9)                69 (17.3)              0.02
   Previous CABG, *n* (%)                    14 (1.5)                2 (0.4)                  21 (5.3)               \<0.01
   Hypertension, *n* (%)                     576 (61.7)              294 (64.1)               246 (61.5)             0.66
   Diabetes mellitus, *n* (%)                302 (32.4)              154 (33.6)               162 (40.5)             0.02
   Hyperlipidemia, *n* (%)                   569 (61.0)              262 (57.1)               260 (65.0)             0.06
   Stroke history, *n* (%)                   41 (4.4)                27 (5.9)                 24 (6.0)               0.33
   Smoke, *n* (%)                            569 (61.0)              242 (52.7)               222 (55.5)             \<0.01
   Family history of CAD, *n* (%)            358 (38.4)              186 (40.5)               156 (39.0)             0.74
   Left main + TVD, *n* (%)                  76 (8.2)                143 (31.8)               65 (16.5)              \<0.01
   SYNTAX score, mean ± SD                   21.7 ± 7.7              29.6 ± 9.0               24.7 ± 10.2            \<0.01
  Medication on discharge, *n* (%)                                                                                   
   Aspirin                                   918 (98.4)              440 (95.9)               371 (92.8)             \<0.01
   Beta-blocker                              844 (90.5)              417 (90.8)               360 (90.0)             0.91
   ACEI                                      446 (47.8)              31 (6.8)                 208 (52.0)             \<0.01
   Statin                                    843 (90.4)              64 (13.9)                345 (86.3)             \<0.01
  Laboratory tests, mean ± SD                                                                                        
   Creatinine (µmol/L)                       79.0 ± 15.6             77.3 ± 18.9              78.7 ± 17.9            0.20
   TC (mmol/L)                               4.7 ± 1.1               4.8 ± 1.2                4.8 ± 1.2              0.33
   LDL-C (mmol/L)                            2.6 ± 0.9               2.8 ± 1.0                2.7 ± 0.9              0.06
   HbA1c (%)                                 6.5 ± 1.7               6.6 ± 1.5                6.8 ± 1.8              0.17
   NT-proBNP (pmol/L)                        668.7 ± 474.3           700.0 ± 484.2            923.2 ± 886.3          \<0.01

ACEI: Angiotensin converting enzyme inhibitor; BMI: Body mass index; CABG: Coronary artery bypass graft; CAD: Coronary artery disease; HbA1c: Hemoglobin A1c; LDL-C: Low density lipoprotein cholesterol; LVEF: Left ventricular ejective fracture; MT: Medical therapy; PCI: Percutaneous coronary intervention; TVD: Triple vascular disease; TC: Total cholesterol; SYNTAX: Synergy Between PCI With Taxus and Cardiac Surgery; NT-proBNP: N-terminal prohormone of brain natriuretic peptide.

In the CABG and MT alone groups, the rate of patients with left main disease was significantly higher compared with the PCI group (31.8% vs. 16.5% vs. 8.2%, respectively, *P* \< 0.01). The rate of statin use in the CABG group was significantly lower than those of the PCI and MT alone groups (13.9% vs. 90.4% vs. 86.3%, respectively, *P* \< 0.01; [Table 1](#T1){ref-type="table"}).

Outcomes {#sec2-7}
--------

A total of 1792 patients completed a median 6.8-year follow-up. Patients undergoing revascularization therapy had significantly lower rates for all-cause death and cardiac death compared with MT alone, and there was no difference between the PCI and CABG groups \[[Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}\]. The rate of repeat revascularization was significantly lower in the CABG group compared with the PCI and MT groups \[[Table 2](#T2){ref-type="table"} and [Figure 2e](#F2){ref-type="fig"}\]. The incidence of myocardial infarction was lower in the CABG and MT alone groups than that in the PCI group \[[Figure 2d](#F2){ref-type="fig"}\]. There was no significant difference for stroke when comparing the three groups \[[Table 2](#T2){ref-type="table"} and [Figure 2f](#F2){ref-type="fig"}\].

###### 

Outcomes for patients treated with PCI, CABG, and MT

  Items                      PCI group (*n* = 933)   CABG group (*n* = 459)   MT group (*n* = 400)   *P*
  -------------------------- ----------------------- ------------------------ ---------------------- --------
  All-cause death            43 (4.6)                19 (4.1)                 62 (15.5)\*,^†^        \<0.01
  MACCE                      256 (27.4)              82 (17.9)\*              131 (32.8)\*,^†^       \<0.01
  Cardiac death              26 (2.8)                9 (2.0)                  39 (9.8)\*,^†^         \<0.01
  Myocardial infarction      91 (9.8)                20 (4.4)^‡^              18 (4.5)\*             \<0.01
  Repeat revascularization   149 (16.0)              21 (4.6)^‡^              45 (11.3)^†^           \<0.01
  Stroke                     37 (4.0)                31 (6.8)^‡^              23 (5.8)\*             0.07

Data are shown as *n* (%). \**P* value had significantly difference compared with PCI group; ^†^*P* value had significantly difference compared with CABG group. CABG: Coronary artery bypass graft; MACCE: Main adverse cardiovascular and cerebrovascular events; MT: Medical therapy; PCI: Percutaneous coronary intervention.

![Kaplan-Meier Survival curve among CABG, PCI, and MT alone (a-f). No difference in all-cause death and cardiac death were found between the PCI and CABG groups (a and c). The incidence of myocardial infarction was lower in the CABG and MT alone groups than that in the PCI group (d). The rate of repeat revascularization was significantly lower in the CABG group compared with the PCI and MT groups (e). There was no significant difference for stroke when comparing the three groups (f). CABG: Coronary artery bypass graft; PCI: Percutaneous coronary intervention; MT: Medical therapy.](CMJ-131-1-g002){#F2}

After adjusting for baseline clinical characteristics, PCI and CABG groups maintained a lower risk of all-cause death (PCI: *HR*: 0.35, 95% *CI*: 0.23--0.53, *P* \< 0.01; CABG: *HR*: 0.35, 95% *CI*: 0.18--0.70; *P* \< 0.01) and cardiac death (PCI: *HR*: 0.32, 95% *CI*: 0.19--0.54, *P* \< 0.01; CABG: *HR*:0.36, 95% *CI*: 0.14--0.93, *P* = 0.03, respectively), compared with MT alone group \[[Table 3](#T3){ref-type="table"}\]. CABG patients had a lower risk of repeat revascularization than did patients in the PCI and MT alone groups. An increased risk of myocardial infarction remained in the PCI group compared with the MT alone group; however, the difference disappeared when comparing the PCI group with the CABG group. The risk of stroke did not differ among three groups.

###### 

Outcomes according to treat strategy

  Items                      Unadjusted *HR* (95% *CI*)   *P*      Adjusted *HR* (95% *CI*)   *P*
  -------------------------- ---------------------------- -------- -------------------------- --------
  All-cause death                                                                             
   PCI versus MT             0.26 (0.18--0.38)            \<0.01   0.35 (0.23--0.53)          \<0.01
   CABG versus MT            0.25 (0.15--0.41)            \<0.01   0.35 (0.18--0.70)          \<0.01
   CABG versus PCI           0.96 (0.56--1.65)            0.88     1.00 (0.50--2.02)          0.99
  MACCE                                                                                       
   PCI versus MT             0.85 (0.68--1.06)            0.15     0.95 (0.75--1.20)          0.64
   CABG versus MT            0.51 (0.38--0.69)            \<0.01   0.49 (0.34--0.71)          \<0.01
   CABG versus PCI           0.60 (0.46--0.78)            \<0.01   0.52 (0.36--0.73)          \<0.01
  Cardiac death                                                                               
   PCI versus MT             0.25 (0.15--0.41)            \<0.01   0.32 (0.19--0.54)          \<0.01
   CABG versus MT            0.19 (0.09--0.38)            \<0.01   0.36 (0.14--0.93)          0.03
   CABG versus PCI           0.75 (0.35--1.60)            0.46     1.14 (0.43--3.05)          0.79
  Myocardial infarction                                                                       
   PCI versus MT             1.92 (1.16--3.19)            0.01     2.04 (1.22--3.42)          \<0.01
   CABG versus MT            0.90 (0.48--1.70)            0.74     1.14 (0.53--2.46)          0.73
   CABG versus PCI           0.47 (0.29--0.76)            \<0.01   0.56 (0.29--1.08)          0.08
  Repeat revascularization                                                                    
   PCI versus MT             1.30 (0.93--1.81)            0.12     1.33 (0.95--1.87)          0.10
   CABG versus MT            0.36 (0.22--0.61)            \<0.01   0.29 (0.16--0.53)          \<0.01
   CABG versus PCI           0.28 (0.18--0.44)            \<0.01   0.22 (0.13--0.39)          \<0.01
  Stroke                                                                                      
   PCI versus MT             0.59 (0.35--0.99)            0.05     0.75 (0.44--1.28)          0.29
   CABG versus MT            1.11 (0.65--1.91)            0.70     0.82 (0.41--1.64)          0.57
   CABG versus PCI           1.89 (1.17--3.04)            \<0.01   1.09 (0.56--2.11)          0.80

CABG: Coronary artery bypass graft; *CI*: Confidence interval; *HR*: Hazard ratio; MACCE: Main adverse cardiovascular and cerebrovascular events; MT: Medical therapy; PCI: Percutaneous coronary intervention.

Subgroup analysis {#sec2-8}
-----------------

No significant difference was found between the PCI and CABG groups for the risk of all-cause death \[[Figure 3a](#F3){ref-type="fig"}\]. However, this risk was lower in both the PCI and CABG groups compared with MT alone except for the subgroups with LVEF \<40%, SYNTAX score \<22, and SYNTAX score \>32 \[Figure [3b](#F3){ref-type="fig"} and [3c](#F3){ref-type="fig"}\].

![Subgroup analysis of all-cause mortality. No significant difference was found between the PCI and CABG groups for the risk of all-cause mortality (a). This risk was lower in both the PCI and CABG groups compared with MT alone except for the subgroups with LVEF \<40%, SYNTAX score \<22, and SYNTAX score \>32 (b and c). DM: Diabetes mellitus; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass graft; MT: Medical therapy; LVEF: Left ventricular ejection fraction; SYNTAX: Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery.](CMJ-131-1-g003){#F3}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

PTVD patients have a relatively long life expectancy and therefore, a longer exposure to potentially aggressive progressive coronary atherosclerosis, which leads to a high risk of recurrent coronary events and repeat revascularization.\[[@ref1]\] Prognosis evaluation and treatment strategy selection in these patients is an active research focus. In this study, we enrolled all PTVD patients and avoided the limitation of randomized trials of having highly selective populations. To our knowledge, our study is the largest single-center clinical cohort study assessing long-term outcomes of PTVD patients to date. After a median 6.8-year follow-up, patients undergoing PCI and CABG both showed lower all-cause death and cardiac death rates compared with MT alone, and patients receiving MT alone had the worst long-term clinical outcomes. Compared with PCI, CABG patients had a lower incidence of repeat revascularization.

Previous studies evaluated the effects of treatment in patients with premature coronary heart disease, but no studies involved TVD patients and none compared the long-term outcomes of different treatment strategies. The Coronary aRtery diseAse in younG adultS study (CRAGS study) is the only previous study that analyzed PCI or CABG in patients aged ≤50 years.\[[@ref10][@ref11]\] Results showed that PCI and CABG were both associated with lower risk of all-cause death and that CABG was associated with a lower risk of myocardial infarction and repeat revascularization, similar to our results. However, the CRAGS study did not compare different MTs, and the median follow-up time was only 3 years. Furthermore, the outcomes of PCI and CABG in the CRAGS study were analyzed separately in two independent and different patient populations, making the results noncomparable. The PCI patients were also classified only by clinical symptom and not by the number of diseased vessels, and CABG patients were not limited strictly to TVD but instead were defined as having at least double-vessel disease. In our study, we analyzed the long-term (median: 6.8 years) outcomes of three treatment strategies including PCI, CABG, and MT alone in patients with confirmed PTVD in a unified population who received different treatments almost at the same time interval, which made the results more comparable.

CABG is considered the best treatment for patients with TVD.\[[@ref12][@ref13]\] Most previous studies comparing outcomes of CABG and PCI in patients with multivessel coronary disease suggest that long-term mortality following CABG is better than for PCI.\[[@ref14][@ref15][@ref16]\] Brener *et al*.\[[@ref17]\] enrolled 6033 consecutive patients undergoing revascularization; PCI was performed in 872 patients, and 5161 patients underwent CABG. The study showed that PCI was associated with an increased risk of death; however, with improved interventional operation skill and technology, especially after the using of new generation drug-eluting stents,\[[@ref18]\] PCI has been increasingly chosen in patients with more complex disease including TVD. Recent studies have shown that PCI is associated with a similar risk of death compared with CABG in patients with multivessel disease,\[[@ref19][@ref20]\] especially in patients with lower SYNTAX score.\[[@ref21][@ref22]\] However, these studies focused only on TVD patients, not PTVD patients. Our results showed that PCI was associated with equal long-term benefit compared with CABG for all-cause death and cardiac death. Although baseline conditions and coronary anatomical complexity in the PCI group were better than in the CABG group, the better results for all-cause death and cardiac death persisted after adjustment. To our knowledge, our results are the first to show the same therapeutic benefits with PCI and CABG in PTVD patients in a clinical study, indicating that PCI may be an alternative treatment for PTVD patients, with equivalent results to CABG.

The MASS II trial is the only randomized study showing benefits of PCI (with bare metal stents) and CABG over MT alone regarding several primary end points at 10-year follow-up.\[[@ref18]\] However, the study involved patients with multiple-vessel disease, preserved left ventricular function, and did not include PTVD patients. Our study showed that PTVD patients receiving MT alone had the worst outcomes for both all-cause and cardiac death compared with PCI and CABG patients, demonstrating that, at least for PTVD patients, and revascularization therapy with either PCI or CABG is an optimal strategy compared with medication alone.

Randomized controlled trials and meta-analyses including stable multivessel coronary artery disease patients found that CABG was better than PCI when comparing repeat revascularization and myocardial infarction rates.\[[@ref18][@ref23][@ref24][@ref25]\] This result was confirmed in our study. As a result of the higher rates of complete revascularization provided by CABG, myocardial infarction and revascularization rates also decreased. Furthermore, because of the difficulty of post-CABG surgery, revascularization was more difficult to repeat in the CABG group compared with the PCI group. In our study, the incidence of myocardial infarction in the CABG group was significantly lower than in the PCI group before adjustment. However, after adjusting for baseline characteristics, the risk of myocardial infarction was no different when comparing CABG and PCI, possibly because of the significantly lower rate of statin use in the CABG group. These results also reflect the current clinical use of post-CABG MT and the protective effect of statins for myocardial infarction.\[[@ref26]\]

CABG is generally considered to be associated with an increased incidence of stroke.\[[@ref27][@ref28]\] A meta-analysis by Alam *et al*.\[[@ref29]\] demonstrated that CABG had a higher rate of stroke compared with PCI in patients with a mean age of \>70 years. Our results showed that the incidence of stroke was initially higher in the CABG and MT alone groups compared with the PCI group in paired comparisons, but the difference disappeared after adjustment. These findings may be related to the different baseline characteristics in the CABG and MT alone patients who were older, and who had more complications such as diabetes mellitus and more complex coronary artery anatomy. These results suggest that when deciding on treatment options in younger TVD patients, the risk of stroke caused by CABG may not be a consideration.

As current guidelines recommend, the treatment strategy for patients with TVD should be chosen according to the SNYTAX score.\[[@ref30][@ref31]\] In our study, subgroup analysis showed a similar risk for all-cause mortality for PCI and CABG patients in all subgroups, especially with different SNYTAX scores. This result suggests that the long-term outcome efficacy of PCI in PTVD patients may be comparable to CABG and that PCI should also be a treatment option for these patients.

Randomized clinical trials randomly assign patients to standard and investigational arms and follow patients over a defined period; this approach does not necessarily reflect clinical practice.\[[@ref32]\] In our study, we assessed patients without predesigned exclusion criteria, which avoided the selection restrictions of randomized controlled trials and provided better clinical evidence of effectiveness in actual practice;\[[@ref33][@ref34][@ref35][@ref36]\] therefore, our results are more reliable.

There are certain limitations to consider in our study. First, our findings were based on data from a single center, which may limit its generalizability. Second, we performed a baseline patient characteristics adjustment to reduce selection bias to better reflect actual clinical practice; however, because data for certain undefined or unmeasured risk factors related to the treatment choice and to the end points were not collected, bias could be present in our results. Third, patients undergoing complete revascularization or incomplete revascularization cannot be distinguished in this study, which may cause a certain impact on the result of prognosis. Finally, we could not access postdischarge compliance data even though all patients were discharged from the hospital on standard guideline-directed MT.

In conclusion, revascularization therapies, no matter PCI or CABG, both had comparable long-term clinical benefits in PTVD patients. Patients receiving MT alone had the worst long-term clinical outcomes. CABG patients had a reduced risk of repeat revascularization compared with PCI patients.
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